Personalized medicine, which tailors treatment based on individual genetic, environmental, and lifestyle factors, promises significant advancements in healthcare by potentially improving patient outcomes and reducing costs. This review examines cost-effectiveness studies related to personalized medicine, focusing on evidence from various medical conditions, including cancer, cardiovascular diseases, and rare genetic disorders. We analyzed 30 studies published between 2010 and 2023 to assess the economic implications of personalized medicine. Our review reveals that while personalized medicine can lead to improved health outcomes and cost savings, the economic benefits are context-dependent. Key factors influencing cost-effectiveness include disease type, healthcare infrastructure, and implementation costs. This review provides insights for policymakers and healthcare providers and suggests directions for future research.
